Biogen has announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s R&D and technical operations teams alongside its global and North American commercial organizations into a co-located […]

bluebird bio has entered into a definitive agreement to be acquired by private-equity firms Carlyle Group and SK Capital Partners in collaboration with a team of highly experienced biotech executives in a deal worth up to $96 million. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will […]

Stoke Therapeutics has entered into a collaboration with Biogen on the development and commercialization of zorevunersen, a potential first-in-class treatment for a form of epilepsy known as Dravet syndrome. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Upon closing of the transaction, Stoke will […]

In late January, Sage Therapeutics announced that its Board of Directors had unanimously rejected the unsolicited, nonbinding proposal it received from Biogen after concluding that the proposal significantly undervalues Sage and is not in the best interest of its shareholders. (Biogen had offered to acquire all outstanding shares of Sage for $7.22 per share.) In addition, the Board […]